Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07224152 · ClinicalTrials.gov registry record · Phase 1

NBTXR3 With Radiation Therapy Alone for Locally-advanced Non-small Cell Lung Cancer

A Phase 1 study, sponsored by M.D. Anderson Cancer Center.

Recruiting
Registry status
Phase 1
Development phase
40
Enrollment target

NCT07224152: Recruiting Phase 1 study, sponsored by M.D. Anderson Cancer Center.

NCT07224152 is a Phase 1 study that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07224152, a Phase 1 study, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.

RECRUITING
Registry status
Phase 1
Development phase
40 participants
Enrollment target

Study Summary

This is a single institution, single arm phase I/II study of NBTXR3 with radiation therapy for stage I-III advanced non-small cell lung cancer patients who are not candidates for chemotherapy or surgical resection.

Interventions

  • DRUG NBTXR3

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2026-03-27
Est. Completion 2030-08-30
Phase Phase 1

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

What the Registry Record Tells You About NCT07224152

The ClinicalTrials.gov registry entry for NCT07224152 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which NBTXR3 is the first listed.

NCT07224152 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT07224152 about?

NCT07224152 is a clinical study titled "NBTXR3 With Radiation Therapy Alone for Locally-advanced Non-small Cell Lung Cancer". This is a single institution, single arm phase I/II study of NBTXR3 with radiation therapy for stage I-III advanced non-small cell lung cancer patients who are not candidates for chemotherapy or surgical resection.

What is the current status of trial NCT07224152?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2026-03-27. Estimated completion is 2030-08-30.

What interventions are being tested in trial NCT07224152?

The interventions under investigation include: NBTXR3 (DRUG).

Who is sponsoring clinical trial NCT07224152?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.